Last updated: April 23, 2026
Who supplies cimetidine hydrochloride (API) globally?
Cimetidine hydrochloride is a mature, off-patent API with a broad supplier base across China and India, plus specialty distributors and API trading houses. Public product listings and regulatory databases typically show recurring manufacturers under multiple brand and pack formats.
Because “supplier” can mean API manufacturer, intermediate manufacturer (e.g., cyanoethyl/thiourea-sidechemistry inputs), or finished-dose distributor, the practical supplier map for procurement usually breaks into these three buckets.
API supply channels
- API manufacturers (direct)
- Produce cimetidine hydrochloride as a branded or generic API.
- API distributors and trading companies
- Source from one or more API manufacturers and sell with standard documentation (COA, CoC, compliance letters).
- Finished dosage manufacturers (often irrelevant for API procurement)
- Provide tablets/syrups; may not offer API supply directly.
Which countries dominate cimetidine hydrochloride supply?
Procurement for cimetidine hydrochloride is largely concentrated in:
- China
- India
- Europe (smaller footprint for API, larger for secondary distribution)
- United States (mainly distribution and legacy channels rather than new API capacity for a mature API)
What procurement-ready documentation do cimetidine suppliers typically provide?
For regulated API sourcing, buyers usually request:
- Certificate of Analysis (CoA) for each lot
- Certificate of Conformity (CoC) and/or Letter of Compliance
- SDS and GMP status statement
- DMF/ASMF status (where applicable)
- Manufacturing site and quality agreement template for audits
- Analytical methods package (HPLC/UV, impurity profile method references)
This is standard practice for API shipments used in drug manufacturing under GMP expectations (COA and quality documentation are required to release API lots to customers in regulated settings). The requirement framework is reflected in global GMP guidance and ICH Q-series expectations. (See: ICH Q7 and ICH Q3.)
What quality standards apply to cimetidine hydrochloride suppliers?
Suppliers that sell into regulated markets typically align with:
- GMP manufacturing expectations for APIs: ICH Q7
- Impurity control: ICH Q3A (small-molecule impurities) and ICH Q3B (residual solvents, as relevant)
- Analytical quality and validation: ICH Q2
Key point for supplier selection is that mature APIs still face scrutiny on:
- Impurity profile consistency (process drift over time)
- Residual solvent controls and polymorph/particle-size controls (when specified)
- Documentation traceability across lots
ICH Q7 establishes GMP for APIs and governs vendor quality systems, documentation, change control, and batch release expectations. (Source: ICH Q7).
ICH Q3A/Q3B drive impurity and residual solvent limits and reporting practices. (Sources: ICH Q3A, ICH Q3B).
ICH Q2 governs validation and analytical method expectations. (Source: ICH Q2).
How should procurement teams structure supplier qualification for cimetidine hydrochloride?
A workable qualification approach for a mature API like cimetidine hydrochloride:
- Vendor documentation pack
- GMP compliance statement, DMF/ASMF summary (if any), CoA template, SDS, test methods summary.
- Analytical comparability
- Impurity profile and residual solvents versus internal specs and pharmacopeial reference (USP/BP/EP as applicable).
- On-site or remote audit
- Quality unit independence, deviation/CAPA process, change control, data integrity.
- Lot-to-lot consistency testing
- Stability and re-test policy alignment (as used by finished-dose manufacturers).
This workflow aligns with ICH GMP principles for API quality and control. (Source: ICH Q7.)
Which supplier types are most practical for R&D vs production?
R&D procurement (small to medium lots)
- Prefer API manufacturers that can support:
- impurity profile detail
- method transfer packages (or at least method summaries)
- technical support on specs
Commercial production procurement (high volume)
- Prefer:
- validated GMP supply chain
- multi-lot consistency history
- documented change control processes
- ability to support regulatory filings with credible documentation
Where do buyers typically find cimetidine hydrochloride supplier lists?
Supplier discovery for cimetidine hydrochloride usually comes from:
- Regulatory substance and manufacturing listings
- Pharmaceutical procurement catalogs
- API marketplace vendor catalogs
- DMF/ASMF holders (when discoverable)
However, because “supplier” must be tied to a named company to be actionable, the most reliable sources are regulatory submissions and audited listings. Those are not consistently published as simple “supplier name lists” for this mature API.
Key Takeaways
- Cimetidine hydrochloride is a mature, widely supplied API, with procurement supply concentrated in China and India, plus distributor/trading channels into Europe and the US.
- Supplier evaluation should be driven by ICH Q7 GMP alignment, plus ICH Q3A/Q3B impurity and residual solvent controls and ICH Q2 analytical method expectations.
- The highest-probability procurement path is a tiered qualification strategy: document pack review, analytical comparability, and audit/lot consistency checks.
FAQs
1) Are cimetidine hydrochloride API suppliers the same as finished-dose tablet manufacturers?
No. Finished-dose manufacturers may not sell API directly. Procurement for APIs typically targets API manufacturers or authorized API distributors.
2) What documentation is most critical when selecting an API supplier for cimetidine hydrochloride?
Per ICH GMP expectations, prioritize CoA/CoC, GMP compliance statements, impurity and residual solvent controls (aligned with ICH Q3A/Q3B), and analytical method validation support (aligned with ICH Q2). (Sources: ICH Q7, ICH Q3A, ICH Q3B, ICH Q2.)
3) Which quality systems matter most for a mature API like cimetidine hydrochloride?
Deviation/CAPA, change control, data integrity, and batch release controls under GMP. These are core expectations in ICH Q7. (Source: ICH Q7.)
4) What tends to cause lot-to-lot problems for mature APIs?
Process drift leading to impurity profile changes, residual solvent variability, and changes in purification or raw material quality controls. These affect compliance under ICH impurity expectations. (Sources: ICH Q3A, ICH Q3B.)
5) Should procurement align cimetidine hydrochloride specs to pharmacopeia or internal targets?
In practice, suppliers must support pharmacopeial compliance and also meet the finished-dose manufacturer’s internal specifications, including impurity and residual solvent limits aligned with ICH guidance. (Sources: ICH Q3A, ICH Q3B.)
References
[1] International Council for Harmonisation (ICH). (2009). ICH Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
[2] International Council for Harmonisation (ICH). (1996). ICH Q2: Validation of Analytical Procedures: Text and Methodology.
[3] International Council for Harmonisation (ICH). (1996). ICH Q3A: Impurities in New Drug Substances.
[4] International Council for Harmonisation (ICH). (1997). ICH Q3B: Impurities in New Drug Products.
